Xtalks Webinars

April is IBS Awareness Month. IBS affects up to 1 in 10 people worldwide, yet many remain undiagnosed. Learn about current and emerging treatments that are improving lives. Read more at buff.ly/xKjWeCW. #IBSAwarenessMonth #ThisIsIBS #GutHealth #IBS

A first for rare metabolic disorder ARG1-D: Immedica's Loargys (pegzilarginase-nbln) wins accelerated FDA approval for the condition, offering a new enzyme-based approach to reduce toxic arginine levels in patients. Read more at buff.ly/90L9xzO. #FDA #FDAApproval #RareDisease #UltrarareDisease

Join us to navigate the "Glomerular Revolution" and transform the medical management of rare kidney diseases with Jonathan Barratt, PhD, and Claudio Hegenberger in this webinar hosted by Emerald Clinical. They will provide a deep dive into the shared pathophysiological drivers of IgAN, PMN, FSGS, and C3G while exploring how the latest breakthrough therapies, from iptacopan to sparsentan, are paving the way for even more effective combination regimens. Register now to gain practical insights into accelerating recruitment and bringing life-changing treatment options to market faster: buff.ly/HARrZ3X #EmeraldClinical #Nephrology #RareDisease #GlomerularRevolution #IgAN #FSGS #C3G #ClinicalTrials #Biomarkers #DrugDevelopment #KidneyHealth #PrecisionMedicine #PediatricResearch

Growth in Asia’s healthcare and life sciences sector is showing up across diagnostics, medtech, digital health, specialty care and healthcare services. See which 25 companies made the Financial Times’ 2026 ranking at buff.ly/b6guYYG by @soumya2390. #HealthcareIndustry #LifeSciences #DigitalHealth #Medtech #AsiaHealthcare

The FDA has approved J&J’s Icotyde (icotrokinra), the first targeted oral peptide for plaque psoriasis. With biologic-like efficacy in a once-daily pill, it could reshape first-line systemic treatment in a psoriasis market dominated by injectables. Read more at buff.ly/9k8E52g. #FDA #Psoriasis #J&J #DrugDevelopment

In this week’s episode, Polaryx CEO Alex Yang shares how the company is aiming to accelerate treatment options for rare, pediatric lysosomal storage disorders. Listen now at buff.ly/2Ut34OY.

April 2 is World Autism Awareness Day, and this year, the UN is emphasizing the need to move beyond awareness toward inclusion and listening to the diverse voices of people with autism. Also learn about new therapeutic advancements and approvals. Read more at buff.ly/gXkIi4m. #AutismDay #Neurodiversity #Inclusion

While stroke care has advanced, major gaps still remain. @Medtronic_NV President Linnea Burman discusses access, global disparities, partnerships and patient-centered innovation shaping stroke care today in this Xtalks Clinical Edge interview at buff.ly/qIkaKst by @soumya2390. #StrokeCare #Neurovascular #MedicalDevices #GlobalHealth #XtalksClinicalEdge

We’re excited to spotlight Xtalks Featured Community Member Mariel Fabro, Managing Partner at Beacon Launch Partners. Her leadership in pioneering catheter-based therapies, surgical systems and wearable platforms reflects the cutting edge of data-driven medtech innovation. Read more at buff.ly/aJzGzxV. #LifeSciences #Medtech #DigitalTherapeutics #RemoteMonitoring #XtalksCommunity

Accelerate your RNA discovery from gene to mRNA and beyond with Shambhavi Shubham, PhD, in this webinar hosted by GenScript. She will explore how an integrated in vitro transcribed (IVT) RNA workflow can compress development timelines for linear mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA) without sacrificing the robust quality control required for downstream success. Register now to learn how modality-specific design and coordinated RNA-LNP development can minimize experimental iteration and de-risk your path to the clinic: buff.ly/gUdtAOv #GenScript #RNATherapeutics #mRNA #circRNA #saRNA #DrugDiscovery #LNP #Biotechnology #GeneToProtein #IVT #VaccineDevelopment #ClinicalResearch #LifeSciences

The FDA has approved J&J’s Icotyde (icotrokinra), the first targeted oral peptide for plaque psoriasis. With biologic-like efficacy in a once-daily pill, it could reshape first-line systemic treatment in a psoriasis market dominated by injectables. Read more at buff.ly/9k8E52g. #FDA #Psoriasis #J&J #DrugDevelopment

UCB is expanding its US footprint with a $2B biologics manufacturing facility in Georgia that will create 330+ jobs and a projected $5B economic impact. Read more at buff.ly/fwrVRvj. #Biotech #PharmaManufacturing #Biologics

FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer. Developed by Corcept, the therapy targets cortisol pathways to improve chemo response. Read more about the Phase III data by @soumya2390 at buff.ly/2jbzXYr. #CorceptTherapeutics #OvarianCancer #OncologyResearch #DrugApproval #FDAApproval

The FDA has approved the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), a rare, often fatal genetic immune disorder in children. Kresladi is a one-time therapy that could replace risky transplants. Read more at buff.ly/T8jr0Za. #GeneTherapy #RareDisease #FDAApproval

The FDA has approved Novo Nordisk’s once-weekly insulin injection Awiqli, the first basal insulin for adults with type 2 diabetes that replaces daily injections with just one shot a week. Read more at buff.ly/fNERMfM. #Insulin #Diabetes #Type2Diabetes #NovoNordisk

TransPerfect Life Sciences’ Mark Wade explores how AI is being used across clinical development and why linguistic validation still requires careful human oversight. Watch the Xtalks Spotlight video and read the full article at buff.ly/kEvb71s. #AI #MachineLearning #ClinicalDevelopment #DrugDevelopment #COA #eCOA #TransPerfect

Medpace experts Dr. Ann Woolfrey, Tanya Konovalenko and Jackie Widmer explore how customizable platform trials, evolving regulatory pathways and advances in gene therapy are reshaping rare disease clinical development. Read more at buff.ly/U0LE2yW by Mohammad Ali, PhD. #ClinicalResearch #ClinicalTrials #DrugDevelopment #RareDisease #RareDiseaseClinical Trials #GeneTherapy

Stop the $90 billion revenue drain and secure your brand’s future with Gerard Rivera and Stephen Hom in this on-demand webinar hosted by RIS Rx. Our speakers dive deep into the systemic failures of modern copay programs, exploring how accumulators, maximizers, and misaligned industry dynamics erode Gross-to-Net (GTN) performance and disrupt critical patient care. Discover why retrospective audits are no longer sufficient to protect your bottom line and how real-time intervention at the point of enrollment can identify benefit design issues before they cause leakage. In addition, gain the practical strategies needed to improve revenue predictability and ensure patients maintain continuity of care without the friction of unexpected financial barriers. Access now: buff.ly/2Msqphi #RISRx #GrossToNet #GTN #PharmaRevenue #MarketAccess #PatientAccess #RevenueProtection #OnDemand #DrugPricing #PharmaStrategy #SpecialtyPharmacy #HealthcareFinance

Move beyond the numbers and operationalize true representation in clinical research with Antonio Drea, Candy Vila, PharmD, Deena Shaar, Kim Cohee, Tobias Kruse, and Jenifer Ngo Waldrop in this webinar hosted by TransPerfect. Drawing on real-world experience across medical affairs and patient advocacy, our speakers will examine how inclusive trial design, community partnerships, and culturally relevant communication can bridge longstanding gaps in access. Register now to learn how to build a roadmap for trials that reflect the communities they serve, with a special focus on the unique challenges of rare diseases like sickle cell disease, and discover how to drive lasting health equity and improve study outcomes: buff.ly/k5fLI52 #TransPerfect #ClinicalTrials #DiversityInResearch #HealthEquity #PatientAdvocacy #SickleCellDisease #RareDisease #ClinicalOperations #Inclusion #PatientEngagement #MedicalAffairs #DEI #DrugDevelopment

Niels Riedemann, MD, PhD, Founder and CEO of InflaRx, shares how advances in complement science are influencing drug development in immunology and expanding treatment possibilities across inflammatory diseases. Read more at buff.ly/RIfIgmJ.